Ardent Health (ARDT) president granted 32,408 performance-based shares

Q: Was the Ardent Health (ARDT) Ethan Chernin Form 4 a stock purchase or a grant?

The Form 4 reflects a grant, not an open-market purchase. The 32,408 Common Stock shares were acquired under a performance-based restricted stock unit award, with a reported price per share of $0.0000, indicating compensation rather than a market transaction.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Chernin Ethan reported acquisition or exercise transactions in this Form 4 filing.

Ardent Health, Inc. President of Health Services Ethan Chernin reported receiving a grant of 32,408 shares of Common Stock as compensation, with no purchase price paid per share.

These shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units awarded on July 18, 2024. They will vest on December 31, 2026, contingent on continued service through that date. After this award, Chernin directly holds 68,396 shares of Ardent Health common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chernin Ethan

Role President of Health Services

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	32,408	$0.00	--

Holdings After Transaction: Common Stock — 68,396 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/13/2026 - 04:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chernin Ethan

(Last)

(First)

(Middle)

340 SEVEN SPRINGS WAY, SUITE 100

(Street)

BRENTWOOD

37027

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Ardent Health, Inc. [ ARDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President of Health Services

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/11/2026		A		32,408⁽¹⁾	A	$0	68,396	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares earned based on 2024 and 2025 performance under performance vesting restricted stock units awarded on July 18, 2024. Pursuant to the terms of the award, the shares will vest on December 31, 2026 contingent upon service through such date.

Remarks:

	/s/ Stephen C. Petrovich, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Ardent Health (ARDT) report for Ethan Chernin?

Ardent Health reported a compensation-related share grant to Ethan Chernin. He received 32,408 shares of Common Stock at no cost, earned under performance-vesting restricted stock units tied to 2024 and 2025 performance, increasing his direct holdings to 68,396 shares.

Was the Ardent Health (ARDT) Ethan Chernin Form 4 a stock purchase or a grant?

The Form 4 reflects a grant, not an open-market purchase. The 32,408 Common Stock shares were acquired under a performance-based restricted stock unit award, with a reported price per share of $0.0000, indicating compensation rather than a market transaction.

What performance period is tied to Ethan Chernin’s new Ardent Health (ARDT) shares?

The granted shares were earned based on 2024 and 2025 performance. They arise from performance-vesting restricted stock units awarded on July 18, 2024, which measure company or individual performance over those two years before determining the number of shares earned.

When do Ethan Chernin’s new Ardent Health (ARDT) shares vest?

The granted shares are scheduled to vest on December 31, 2026. Vesting is contingent on Mr. Chernin’s continued service through that date, meaning he must remain with the company until then to fully secure the award.

How many Ardent Health (ARDT) shares does Ethan Chernin hold after this Form 4?

After the reported transaction, Ethan Chernin directly holds 68,396 shares. This total includes the 32,408 Common Stock shares granted under the performance-vesting restricted stock units, as disclosed in the Form 4 filing.

What type of equity award did Ardent Health (ARDT) use for Ethan Chernin?

Ardent Health used performance-vesting restricted stock units (RSUs). The RSUs were granted on July 18, 2024, earned based on 2024 and 2025 performance, and convert into shares that vest on December 31, 2026, subject to continued service.